Immune checkpoint inhibitors (ICIs) are effective in classical Hodgkin lymphoma (cHL), but immune-related adverse events (irAEs) may lead to treatment interruption in some patients. We conducted a retrospective cohort study of 145 patients with cHL treated with ICIs between 2015 and 2024. Cohort 1 included 130 patients...
Greater weight at birth, in childhood, and in late adolescence were all associated with greater risk of NHL, and overall associations did not substantively vary by major NHL subtype.
G. Cholack, G. Kleinstern, Dennis P. Robinson et al.· Cancers· 0 citations
The clinical paradigm for treatment of classical Hodgkin lymphoma has been transformed by the use of anti-PD-1 therapy, driven by foundational work revealing near-universal 9p24.1 alterations resulting in overexpression of PD-L1 and PD-L2 on Reed-Sternberg cells. Use of PD-1 inhibitors has demonstrated remarkable clini...
J. Day, Stephen M. Ansell· Haematologica· 0 citations
